NetworkNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Reports Q4, FY 2023 Financial Results
SenesTech (NASDAQ: SNES), the rodent-fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest(R), has released its financial results for fiscal year 2023. According to the report, year-to-date 2024 total revenue is up more than 80% compared to YTD 2023 driven by orders for the company’s proprietary Evolve(TM) soft bait. Other highlights from the report show revenue during 2023 increased 17%, reaching $1.2 million compared to $1 million in 2022; gross profit during 2023 was also up, totaling $539,000 compared to $464,000 in 2022, with gross profit margin at 45.2% in 2023 compared to 45.5% in 2022; net loss decreased in 2023, coming…







